Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Audio content above is prompted by the following:
Clinical Cell-Cycle Risk Score: Evolving Prostate Cancer Risk Stratification
Key Clinical Implications
Risk Stratification Advancements
The clinical cell-cycle risk (CCR) score represents a significant paradigm shift in prostate cancer risk assessment, moving beyond traditional NCCN risk groups by providing:
Treatment Decision-Making Insights
Radiation Therapy and Androgen Deprivation Therapy (ADT)
Personalized Treatment Considerations
Risk Reduction and Treatment Thresholds
When evaluating Prolaris reports, clinicians should:
Future Outlook: Genomic Testing Developments
Emerging Research Priorities
Anticipated advancements in the next 5 years include:
Clinician Preparation Recommendations
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.